Abstract ISI
ANNALS OF ONCOLOGY  (2015)

KEYNOTE-010: Phase 2/3 study of pembrolizumab (MK-3475) vs docetaxel for PD-L1-positive NSCLC after platinum-based therapy

Herbst, RS; Kim D.W.; Felip E.; Perez-Gracia, JL; Garon, EB; Han J.Y.; Molina J.; Kim J.H.; Gervais, R; Ahn, MJ; Majem, M; Fidler, MJ; De Castro G.; Garrido M.; Lubiniecki, GM; et. al.